• Avidan O, Bochner RHizi A. The catalytic properties of the recombinant reverse transcriptase of bovine immunodeficiency virus[J]. Virology, 2006, 351(1): 42-57. doi: 10.1016/j.virol.2006.03.012

  • Barboric M, Taube R, Nekrep N. Binding of Tat to TAR and recruitment of positive transcription elongation factor b occur independently in bovine immunodeficiency virus[J]. J Virol, 2000, 74(13): 6039-6044. doi: 10.1128/JVI.74.13.6039-6044.2000

  • Blair W S, Isaacson J, Li X. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors[J]. Antivir Res, 2005, 65(2): 107-116. doi: 10.1016/j.antiviral.2004.11.001

  • Braun M J, Lahn S, Boyd A L. Molecular cloning of biologically active proviruses of bovine immunodeficiency-like virus[J]. Virology, 1988, 167(2): 515-523.

  • Carpenter S, Miller L D, Alexandersen S. Characterization of early pathogenic effects after experimental infection of calves with bovine immunodeficiency-like virus[J]. J Virol, 1992, 66(2): 1074-1083.

  • Garcia J M, Gao A, He P L. High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay[J]. Antivir Res, 2009, 81(3): 239-247. doi: 10.1016/j.antiviral.2008.12.004

  • Geng Y, Kashanchi F, Wood C. Activation of bovine immunodeficiency-like virus expression by bovine herpesvirus type 1[J]. Virology, 1992, 187(2): 832-836. doi: 10.1016/0042-6822(92)90489-C

  • Gonda M A, Oberste M S, Garvey K J. Development of the bovine immunodeficiency-like virus as a model of lentivirus disease[J]. Developments in biological standardization, 1990, 72(): 97-110.

  • Jones J, Rodgers J, Heil M. High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds[J]. Assay Drug Dev Technol, 2007, 5(2): 181-189. doi: 10.1089/adt.2006.040

  • Kalvatchev Z, Walder R, Barrios M. Acquired immune dysfunction in rabbits experimentally infected with an infectious molecular clone of the bovine immunodeficiency virus (BIV127)[J]. Viral Immunol, 1995, 8(3): 159-164. doi: 10.1089/vim.1995.8.159

  • Krah D L. A simplified multiwell plate assay for the measurement of hepatitis A virus infectivity[J]. Biologicals, 1991, 19(3): 223-227. doi: 10.1016/1045-1056(91)90039-M

  • Li S, Zhu J, Peng Y. Characterization of BIV Env core: implication for mechanism of BIV-mediated cell fusion[J]. Biochem Biophys Res Commun, 2005, 329(2): 603-609. doi: 10.1016/j.bbrc.2005.01.160

  • Liu S H, Chen H X, Chen J T. Isolation and identification of a bovine spuma virus isolate 3026[J]. Virol Sin, 1997, 13(2): 140-145.

  • Liu Z Q, Sheridan D, Wood C. Identification and characterization of the bovine immunodeficiency-like virus tat gene[J]. J Virol, 1992, 66(8): 5137-5140.

  • Mak C C, Brik A, Lerner D L. Design and synthesis of broad-based mono-and bi-cyclic inhibitors of FIV and HIV proteases[J]. Bioorg Med Chem, 2003, 11(9): 2025-2040. doi: 10.1016/S0968-0896(03)00054-3

  • Norelli S, El D S, D'Ostilio D. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1[J]. Curr HIV Res, 2008, 6(4): 306-317. doi: 10.2174/157016208785132527

  • Ochsenbauer-Jambor C, Jones J, Heil M. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication[J]. Biotechniques, 2006, 40(1): 91-100. doi: 10.2144/000112072

  • Pifat D Y, Ennis W H, Ward J M. Persistent infection of rabbits with bovine immunodeficiency-like virus[J]. J Virol, 1992, 66(7): 4518-4524.

  • St-Louis M C, Cojocariu M, Archambault D. The molecular biology of bovine immunodeficiency virus: a comparison with other lentiviruses[J]. Animal health research reviews / Conference of Research Workers in Animal Diseases, 2004, 5(2): 125-143. doi: 10.1079/AHR200496

  • Tobin G J, Ennis W H, Clanton D J. Inhibition of bovine immunodeficiency virus by anti-HIV-1 compounds in a cell culture-based assay[J]. Antivir Res, 1996, 33(1): 21-31. doi: 10.1016/S0166-3542(96)00990-4

  • Wang D, Geng Y Q, Xu W R. An experimental model for screening anti-AIDS drugs with bovine immunodef iciency virus[J]. Chin J Pharmacol Toxicol, 1996, 10(1): 49-52.

  • Xuan C, Qiao W, Li J. BTat, a trans-acting regulatory protein, contributes to bovine immunodeficiency virus-induced apoptosis[J]. Cell Microbiol, 2008, 10(1): 31-40.

  • Xuan C H, Qiao W T, Li J. BTat, a trans-acting regulatory protein, contributes to bovine immunodeficiency virus-induced apoptosis[J]. Cell Microbiol, 2008, 10(1): 31-40.

  • Yang G, Paintsil E, Dutschman G E. Impact of Novel HIV-1 Reverse Transcriptase Mutations, P119S and T165A on 4'-ethynylthymidine Analog Resistance Profile[J]. Antimicrob Agents Chemother, 2009, (): -.

  • Yang Y S, Chen G M, Dong W P. Construction and analysis of activity of an HIV-1/bovine immunodeficiency virus chimeric clone cDNA[J]. Chin J Exp clin virol, 2003, 17(2): 143-145.

  • Zheng L, Swanson M, Liao J. Cloning of the bovine immunodeficiency virus gag gene and development of a recombinant-protein-based enzyme-linked immunosorbent assay[J]. Clin Diagn Lab Immunol, 2000, 7(4): 557-562.